Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

摘要: The development of combination chemotherapy regimens for the treatment advanced Hodgkin's disease and aggressive non-Hodgkin's lymphoma are historical landmarks in oncology. Over 70% patients with Hodgkig's will be cured following administration MOPP [chlormethine (mustine), vincristine, procarbazine prednisolone] or MOPP-derived (Henry-Amar & Somers 1990); and, whereas cyclophosphamide, doxorubicin (adriamycin), vincristine prednisolone (CHOP) is less successful therapy intermediate high grade lymphoma, complete remission (CR) rates 60 to 85% prolonged survival around 30% patients, advent such still represented a dramatic advance. These cytotoxic regimens, certain adaptations, have now become established as standard these diseases, but further progress has been slow. Oncologists attempted develop refine more effective toxic therapies at first presentation, also relapse, by number means.